As U.S. Pharmaceutical Companies Look to Continue Improving Patient Health, Over 40 Brands Select Dendrite to Enhance Patient Adherence.

BEDMINSTER, N.J. -- Dendrite's Adherence Programs Aimed at Integrating Relationships between Patient, Physician, Pharmacy, Managed Care and the Brand

Dendrite International, Inc., (NASDAQ: DRTE) a leading provider of pharmaceutical industry solutions, has been quickly growing its U.S. adherence programs, with 42 distinct pharmaceutical brands adopting this service, and more than 12 million loyalty cards in patients' hands during the past 12 months. The growing adoption of these programs reflects the industry's embrace of strategies that foster patient adherence to therapy prescribed by doctors to help achieve better patient health outcomes. Dendrite has had a growing presence as an innovator of these strategic programs.

Dendrite's proprietary adherence programs are designed to integrate the patient, prescriber, pharmacy and managed care organization. Multi-channel interventions are deployed by Dendrite in these initiatives, including one of the industry's leading adjudicated card programs with access to approximately 97 percent of the major retail pharmacies nationwide, ensuring maximum ease of use for engaged patients.

The uptake of Dendrite's adherence programs comes at a time when recent industry estimates indicate that between 15-25 percent of total prescriptions remain unfilled, while approximately 30-40 percent of patients never refill a prescription in spite of doctors' orders -- all potentially causing a serious impact on patient health, while placing a significant strain on the healthcare system.

"Our proprietary adherence programs are built on the foundation of relationship marketing and enable an interactive, completely customized dialog between the brand and its customers," said Rick Rose, vice president and general manager for Dendrite Marketing Solutions. "Our adherence programs make it easy for brands to deliver comprehensive adherence solutions that integrate all customer constituencies. Today, increasing numbers of our clients are centralizing cross-brand adherence efforts within Dendrite Marketing Solutions because of our superior pharmacy reach and because our proprietary approach and campaign management platform enables rapid, scalable, and cost-efficient implementation."

About Dendrite

Founded in 1986, Dendrite International (NASDAQ: DRTE) enables sales, marketing, clinical and compliance solutions for the global, pharmaceutical industry. The Company's clients are located in more than 50 countries and include the world's top 20 pharmaceutical companies. For more information, please visit www.dendrite.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for certain of our solutions; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; integrating the entities we acquire; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.